Skip to main content

Table 3 Observed change from baseline to 76/80 weeks by region for outcome measure scores

From: Alzheimer’s disease progression by geographical region in a clinical trial setting

  North America Western Europe/Israel South America Eastern Europe/Russia Japan Asia Australia/South Africa Overall
( n = 832) ( n = 412) ( n = 196) ( n = 195) ( n = 191) ( n = 169) ( n = 84) ( N = 2,079)
ADAS-cog11         
 6 months 1.62 (5.66) 1.99 (6.12) 0.99 (6.51) 3.06 (7.23) 0.68 (5.04) 0.21 (6.06) 1.64 (5.97) 1.55 (6.00)
 12 months 3.88 (7.40) 4.92 (7.76) 3.23 (7.28) 6.53 (9.11) 3.18 (6.57) 1.49 (7.04) 5.44 (8.39) 4.07 (7.62)
 18 months 6.04 (9.44) 7.46 (9.68) 4.76 (8.41) 10.95 (10.77) 4.41 (7.99) 3.52 (7.98) 7.3 (11.54) 6.23 (9.48)
ADCS-ADL         
 6 months −3.2 (7.45) −3.41 (8.90) −1.17 (9.09) −2.07 (8.63) −2.03 (6.78) −2.05 (7.86) −2.29 (9.82) −2.71 (8.12)
 12 months −6.26 (10.01) −6.08 (11.08) −3.7 (9.79) −6.39 (12.80) −4.13 (8.76) −4.71 (10.02) −6.18 (13.12) −5.66 (10.51)
 18 months −9.16 (12.13) −10.84 (13.44) −5.57 (12.78) −11.51 (14.16) −5.94 (9.39) −7.85 (9.75) −9.00 (14.89) −8.95 (12.48)
MMSE         
 6 months
 12 months −2.29 (3.56) −2.14 (3.84) −1.39 (3.49) −3.48 (4.73) −1.79 (3.34) −2.22 (2.92) −2.45 (3.79) −2.21 (3.68)
 18 months −3.39 (4.59) −3.66 (4.70) −2.52 (4.18) −5.28 (5.95) −2.78 (4.13) −2.93 (4.06) −3.45 (4.73) −3.38 (4.60)
CDR-SB         
 6 months 5.77 (3.06) 6.19 (3.24) 6.75 (3.18) 7.59 (3.82) 5.64 (3.31) 5.12 (2.74) 6.25 (3.11) 6.05 (3.24)
 12 months 6.47 (3.46) 6.77 (3.67) 7.15 (3.47) 8.74 (4.09) 6.32 (3.71) 5.91 (3.24) 7.45 (3.86) 6.75 (3.64)
 18 months 6.98 (3.91) 7.23 (3.98) 7.09 (3.59) 9.72 (4.66) 6.32 (3.92) 6.25 (3.25) 7.90 (4.32) 7.10 (3.96)
NPI         
 6 months 0.73 (9.52) 0.87 (10.43) 0.00 (11.04) 0.09 (10.79) −0.05 (6.79) 0.71 (9.47) 0.68 (10.73) 0.55 (9.77)
 12 months 1.57 (11.15) 0.63 (11.25) 0.81 (13.48) 0.82 (10.88) 2.04 (9.09) 2.02 (12.76) 2.44 (11.46) 1.37 (11.30)
 18 months 2.86 (13.36) 2.97 (13.98) −1.80 (14.08) 2.30 (12.57) 2.41 (8.95) 1.83 (10.00) 5.29 (14.11) 2.47 (13.11)
  1. Data presented as mean (standard deviation). ADAS-cog11, 11-item Alzheimer’s disease Assessment Scale – cognitive subscale; ADCS-ADL, Alzheimer’s disease Cooperative Study – Activities of Daily Living; CDR-SB, Clinical Dementia Rating Scale sum of boxes; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory.